ライフサイエンスコーパス: cold ischemic time

1 point of retrieval, and so does not include cold ischemic time.

2 hepatitis C virus + serology, donor age and cold ischemic time.

3 ric transplantation and cases with prolonged cold ischemic time.

4 t on portal venous lactate concentration and cold ischemic time.

5 diatric transplants and cases with prolonged cold ischemic times.

6 transplants (1.556, P<0.01), with prolonged cold ischemic time (1.097, P=0.03), for black recipients

7 rm ischemia time greater than 30 minutes and cold ischemic time also occurred over the same period.

8 0009), anastomotic time (P=0.0012), combined cold ischemic time and anastomotic time (P=0.00018), and

9 riate analyses accounting for the effects of cold ischemic time and donor age, Treg suppressive funct

10 s associated with first transplants, shorter cold ischemic time and operative time, and less intraope

11 Prolonged cold ischemic time and recipient life support were predi

12 e of edema, donor/recipient HLA-DR mismatch, cold ischemic time, and donor age were independently ass

13 fferences in the first warm ischemic period, cold ischemic time, and donor age.

14 BC included older age at transplant, shorter cold ischemic time, and single strictures.

15 phics, blood product use, primary diagnosis, cold ischemic time, and surgeon were similar between the

16 r disease, diabetes status, body mass index, cold ischemic time, and UNOS status.

17 aphics, primary diagnosis, surgeon, warm and cold ischemic times, and blood product use were recorded

18 quency of poor ex vivo perfusion, had longer cold ischemic times, and were transplanted into older re

19 Increased cold ischemic time but neither donor age nor intensity o

20 yte antigen mismatches (chi-square 3.06) and cold ischemic time (chi-square 3.23).

21 l, 149 renal transplants were performed with cold ischemic times (CI) greater than 16 hr (UW 87, HTK

22 We also examined the relationship between cold ischemic time (CIT) and likelihood of surgical comp

23 Total cold ischemic time (CIT) consisted of the time from retr

24 Multivariate analysis revealed that cold ischemic time (CIT) greater than 8 hours (HR: 2.46;

25 We stratified on basis of cold ischemic time (CIT) to determine the interaction of

26 Mean cold ischemic time (CIT) was 5.4 hours in O and 7.3 hour

27 The degree of HLA matching, the cold ischemic time (CIT), the balance of exchange, and g

28 Long cold ischemic time (CIT), with or without delayed graft

29 of pulsatile perfusion (PP) across different cold ischemic times (CIT) within different donor groups

30 of diabetes, body mass index, waiting time, cold ischemic time, delayed graft function, and coronary

31 , but not long-term, graft survival, whereas cold ischemic time did not have statistically significan

32 tivariate logistic regression accounting for cold ischemic time, donor age, previous transplant, and

33 erence between the two groups with regard to cold ischemic time for organ storage, donor age, recipie

34 The mean cold ischemic times for the kidney and the pancreas were

35 egionally and shared nationally, livers with cold ischemic time >12 hours, livers from hepatitis C vi

36 tive antibodies (PRAs) (>20%), and prolonged cold ischemic times (>24 hours) in each group.

37 ant and graft loss, cause of graft loss, and cold ischemic time in the geriatric population.

38 y was to examine whether older donor age and cold ischemic time interact to produce inferior allograf

39 slet isolations (donor age 41-59, BMI 26-38, cold ischemic time < 10 h).

40 y mass index <35, non-status 1 registration, cold ischemic time <8 hours, and either hepatocellular c

41 ause they are typically young and have short cold ischemic times, may be advantageous for HCV-infecte

42 42.0%, P < .001), despite a slightly longer cold ischemic time (median: 14.8 vs 14.1 hours, P < .001

43 schemia/reperfusion injury by prolonging the cold ischemic time of the allograft did not affect the s

44 FEV1 achieved, age and gender of the donor, cold ischemic time of the graft, and matching of CMV ser

45 rshall's solution was associated with longer cold ischemic time, older donors, kidney-only donors, do

46 cytomegalovirus (CMV) status or blood type, cold ischemic times, or the incidence of outflow obstruc

47 virus infection (4.9%, P = 0.001) and longer cold ischemic time (P = 0.001).

48 entration (p =.029) and inversely with graft cold ischemic time (p =.007).

49 erative transfusion requirements (P=0.0001), cold ischemic time (P<0.0001), use of roux-en-Y biliary

50 e of death (P=0.0053), donor age (P=0.0017), cold ischemic time (P=0.0009), anastomotic time (P=0.001

51 c artery thrombosis (P=0.0018) and prolonged cold ischemic time (P=0.034), were independent risk fact

52 of type (DCD vs DBD), donor age, steatosis, cold ischemic time, peak aspartate transaminase, day 5 b

53 If cold ischemic time was > or =24 hr, there was a 2.19-fol

54 The mean cold ischemic time was 16.5 hr in the two-layer group ve

55 Mean cold ischemic time was longer in DKT (22.2+/-9.7 hr), bu

56 Cold ischemic time was significantly longer in patients

57 Cold ischemic times were similar between groups, but mor

58 Warm and cold ischemic times were typically <45 min and <90 min,